Table 3.

Multivariable Analysis Showing Those Baseline Factors Independently Associated With Achievement of Deep Steroid-Free Remission at Week 14 (Infliximab and Vedolizumab) or Week 16 (Ustekinumab)

Baseline variable	Adjusted OR	95% CI	P value
Previous exposure to a biologic	3.49	1.43–8.53	<.01a
Age (OR per year)	1.01	1.04–0.97	.76
Visceral adipose tissue (OR per IA-VAT% of body mass)	0.40	0.16–0.98	.03a
Total body fat (OR per % of body mass)	0.97	0.92–0.98	.19
Baseline C-reactive protein (OR per mg/dL)	0.72	1.02–1.09	.03a
Baseline albumin (OR per g/dL)	0.58	0.05–6.71	.67
Drug level higher than the median within the populationbc	2.97	1.20–7.32	.02a

^aStatistically significant.

^bStratified by each drug group: infliximab, vedolizumab, and ustekinumab.

^cMedian drug levels were 9.8, 11.1, and 4.9 mg/dL for infliximab, vedolizumab, and ustekinumab, respectively.